| The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides M Meyrath, M Szpakowska, J Zeiner, L Massotte, MP Merz, T Benkel, ... Nature communications 11 (1), 3033, 2020 | 93 | 2020 |
| A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast CancerFibroblast CXCL14/ACKR2/NOS1 Signaling in … E Sjöberg, M Meyrath, L Milde, M Herrera, J Lövrot, D Hägerstrand, ... Clinical cancer research 25 (12), 3702-3717, 2019 | 90 | 2019 |
| Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture C Harak, M Meyrath, I Romero-Brey, C Schenk, C Gondeau, P Schult, ... Nature microbiology 2 (3), 1-14, 2016 | 61 | 2016 |
| Different contributions of chemokine N‐terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3 M Szpakowska, AM Nevins, M Meyrath, D Rhainds, T D'huys, ... British Journal of Pharmacology 175 (9), 1419-1438, 2018 | 56 | 2018 |
| Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds E Wouters, J Walraed, MJ Robertson, M Meyrath, M Szpakowska, ... ACS pharmacology & translational science 3 (2), 285-295, 2019 | 49 | 2019 |
| Multiple drugs compete for transport via the Plasmodium falciparum chloroquine resistance transporter at distinct but interdependent sites S Bellanca, RL Summers, M Meyrath, A Dave, MN Nash, M Dittmer, ... Journal of Biological Chemistry 289 (52), 36336-36351, 2014 | 48 | 2014 |
| Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and … M Szpakowska, M Meyrath, N Reynders, M Counson, J Hanson, ... Biochemical pharmacology 153, 299-309, 2018 | 36 | 2018 |
| CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6 A Chevigné, B Janji, M Meyrath, N Reynders, G D’Uonnolo, T Uchański, ... Cancers 13 (5), 1054, 2021 | 31 | 2021 |
| The diverse and complex roles of atypical chemokine receptors in cancer: From molecular biology to clinical relevance and therapy E Sjöberg, M Meyrath, A Chevigné, A Östman, M Augsten, M Szpakowska Advances in cancer research 145, 99, 2020 | 30 | 2020 |
| CXCL14 preferentially synergizes with homeostatic chemokine receptor systems A Kouzeli, PJ Collins, M Metzemaekers, M Meyrath, M Szpakowska, ... Frontiers in Immunology 11, 561404, 2020 | 27 | 2020 |
| Systematic reassessment of chemokine-receptor pairings confirms CCL20 but not CXCL13 and extends the spectrum of ACKR4 agonists to CCL22 M Meyrath, N Reynders, T Uchański, A Chevigné, M Szpakowska Journal of Leucocyte Biology 109 (2), 373-376, 2021 | 23 | 2021 |
| Atypical opioid receptors: unconventional biology and therapeutic opportunities CB Palmer, M Meyrath, M Canals, E Kostenis, A Chevigné, ... Pharmacology & Therapeutics 233, 108014, 2022 | 19 | 2022 |
| The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7 M Szpakowska, AM Decker, M Meyrath, CB Palmer, BE Blough, ... Signal Transduction and Targeted Therapy 6 (1), 209, 2021 | 19 | 2021 |
| Proadrenomedullin N-Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7 M Meyrath, CB Palmer, N Reynders, A Vanderplasschen, M Ollert, ... ACS Pharmacology & Translational Science 4 (2), 813-823, 2021 | 19 | 2021 |
| Nanoluciferase-based methods to monitor activation, modulation and trafficking of atypical chemokine receptors R Luís, G D’Uonnolo, CB Palmer, M Meyrath, T Uchański, M Wantz, ... Academic Press, 2022 | 8 | 2022 |
| Characterization of a threonine-rich cluster in hepatitis C virus nonstructural protein 5A and its contribution to hyperphosphorylation C Schenk, M Meyrath, U Warnken, M Schnölzer, W Mier, C Harak, ... Journal of virology 92 (24), e00737-18, 2018 | 7 | 2018 |
| The extended N-terminal domain confers atypical chemokine receptor properties to CXCR3-B G D’Uonnolo, N Reynders, M Meyrath, D Abboud, T Uchański, ... Frontiers in Immunology 13, 2194, 2022 | 6 | 2022 |
| The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein–protein interaction in glioblastoma V Neirinckx, AC Hau, A Schuster, S Fritah, K Tiemann, E Klein, ... Neuro-Oncology Advances 1 (1), vdz024, 2019 | 6 | 2019 |
| Nanoluciferase-based complementation assay for systematic profiling of GPCR–GRK interactions CB Palmer, G D'Uonnolo, R Luís, M Meyrath, T Uchański, A Chevigné, ... Methods in Cell Biology 169, 309-321, 2022 | 5 | 2022 |
| Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samples M Meyrath, M Szpakowska, JM Plesseria, O Domingues, J Langlet, ... Methods in Enzymology 675, 351-381, 2022 | 2 | 2022 |
